This company listing is no longer active
Horizon Therapeutics Management
Management criteria checks 2/4
Key information
Tim Walbert
Chief executive officer
US$20.1m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 14.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.7yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$20m | US$1m | US$521m |
| Sep 30 2022 | n/a | n/a | US$574m |
| Jun 30 2022 | n/a | n/a | US$765m |
| Mar 31 2022 | n/a | n/a | US$862m |
| Dec 31 2021 | US$21m | US$1m | US$534m |
| Sep 30 2021 | n/a | n/a | US$552m |
| Jun 30 2021 | n/a | n/a | US$518m |
| Mar 31 2021 | n/a | n/a | US$280m |
| Dec 31 2020 | US$22m | US$1m | US$390m |
| Sep 30 2020 | n/a | n/a | US$792m |
| Jun 30 2020 | n/a | n/a | US$517m |
| Mar 31 2020 | n/a | n/a | US$592m |
| Dec 31 2019 | US$14m | US$1m | US$573m |
| Sep 30 2019 | n/a | n/a | US$82m |
| Jun 30 2019 | n/a | n/a | US$97m |
| Mar 31 2019 | n/a | n/a | US$77m |
| Dec 31 2018 | US$17m | US$1m | -US$38m |
| Sep 30 2018 | n/a | n/a | -US$178m |
| Jun 30 2018 | n/a | n/a | -US$275m |
| Mar 31 2018 | n/a | n/a | -US$460m |
| Dec 31 2017 | US$2m | US$1m | -US$350m |
| Sep 30 2017 | n/a | n/a | -US$495m |
| Jun 30 2017 | n/a | n/a | -US$437m |
| Mar 31 2017 | n/a | n/a | -US$212m |
| Dec 31 2016 | US$2m | US$950k | -US$166m |
Compensation vs Market: Tim's total compensation ($USD20.10M) is above average for companies of similar size in the BR market ($USD5.00M).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
CEO
Tim Walbert (55 yo)
14.8yrs
Tenure
US$20,103,869
Compensation
Mr. Timothy P. Walbert, also known as Tim, is Director of Century Therapeutics, Inc. from October 2022. He had been the Chairman of the Board at Exicure, Inc. since April 2020 until February 4, 2022 and ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.8yrs | US$20.10m | 0.38% $ 503.0m | |
| Executive VP of Finance & CFO | less than a year | US$7.17m | 0.00012% $ 157.7k | |
| Executive VP & General Counsel | 1.1yrs | US$10.87m | 0.0036% $ 4.7m | |
| Advisor | less than a year | US$1.82m | 0.081% $ 107.1m | |
| Executive VP & Chief Strategy Officer | 3.3yrs | US$6.75m | 0.025% $ 32.4m | |
| Executive Vice President of Research & Development | 2yrs | US$8.48m | 0.0064% $ 8.4m | |
| Senior VP & Chief Accounting Officer | less than a year | no data | 0.0028% $ 3.6m | |
| Senior VP & Chief Investor Relations Officer | no data | no data | no data | |
| Executive VP of Corporate Affairs & Chief Communications Officer | 7.3yrs | no data | no data | |
| Senior VP of Corporate Development & Chief of Staff | 1.4yrs | no data | no data | |
| Executive VP | 5.5yrs | US$2.31m | no data | |
| Executive VP & Chief Medical Officer | no data | US$5.86m | 0.10% $ 136.2m |
1.7yrs
Average Tenure
49yo
Average Age
Experienced Management: H1ZN34's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.8yrs | US$20.10m | 0.38% $ 503.0m | |
| Lead Independent Director | 11.5yrs | US$551.24k | 0.032% $ 42.3m | |
| Independent Director | 8.5yrs | US$522.49k | 0.034% $ 44.6m | |
| Independent Director | 15.7yrs | US$504.36k | 0.024% $ 31.5m | |
| Independent Director | 11yrs | US$494.99k | 0.032% $ 41.8m | |
| Independent Director | 8.9yrs | US$506.24k | 0.040% $ 52.5m | |
| Independent Director | 5.6yrs | US$510.61k | 0.019% $ 24.7m | |
| Independent Director | 3.6yrs | US$514.36k | 0.0073% $ 9.6m | |
| Independent Director | 5.6yrs | US$496.24k | 0.019% $ 25.3m |
8.9yrs
Average Tenure
65yo
Average Age
Experienced Board: H1ZN34's board of directors are considered experienced (8.9 years average tenure).